Adult Dosing

Muscle weakness and easy fatigability due to Lambert-Eaton syndrome

• 10-15 mg/kg/day PO divided tid-qid
• May increase gradually to 35 mg/kg/day or or up to the development of side effects
• Max: 35 mg/kg/day

Pediatric Dosing

• Safety and effectiveness in pediatric patients have not been established

[Outline]

• Adult Dosing
• Pediatric Dosing

• Reduce symptoms of muscle weakness and easy fatigability due to Lambert-Eaton syndrome

• Hypersensitivity to any of the ingredients of the product

• N/A

Renal Dose Adjustment

• Renal impairment: Dose adjustments not defined

Hepatic Dose Adjustment

• Hepatic impairment: Dose adjustments not defined

• Guanidine can cause dose related bone-marrow suppression. Perform blood studies at baseline, followed by frequent red and white blood cell and differential counts. On the appearance of bone-marrow suppression, discontinue the drug. Avoid concurrent therapy with other drugs that may cause bone-marrow suppression
• Guanidine therapy can affect renal function. Monitor serum creatinine levels regularly during therapy
• Assess muscle strength and function frequently. Ensure that parenteral atropine is available for emergency treatment of cholinergic crisis
• Do not continue the treatment longer than necessary

Cautions: Use cautiously in

• Renal impairment
• Concomitant use drugs causing bone marrow suppression

Pregnancy Category:NR

Breastfeeding: As guanidine is excreted in human milk, manufacturer advises that a patient receiving guanidine should discontinue breastfeeding.

• CNS: Lightheadedness, jitteriness, irritability, emotional lability, psychotic state, confusion, mood changes, hallucinations
• NEURO: Paresthesia of lips, face, hands, feet, cold sensations in hands and feet, tremor, trembling sensation, ataxia
• CV: Palpitation, tachycardia, atrial fibrillation, hypotension
• GI: Dry mouth, gastric irritation, anorexia, nausea, diarrhea, abdominal cramping
• HEMA: Anemia, leukopenia, thrombocytopenia
• HEPA: Abnormal LFTs
• EENT: Sore throat
• DERM: Rash, flushing or pink complexion, folliculitis, petechiae, purpura, ecchymoses, sweating, skin eruptions, dryness, scaling
• GU: Elevation of blood creatinine, uremia; chronic interstitial nephritis, acute interstitial nephritis, renal tubular necrosis
• MISC: Fever

• Parasympathomimetic; enhances the release of acetylcholine following a nerve impulse ans also slow the rates of depolarization and repolarization of muscle cell membranes
• Rapidly absorbed
• Not metabolized
• Excretion: Unknown
• Half-life: 7-8 hrs

US Trade Name(s)

• Only generic available

US Availability

guanidine (generic)

• TABS: 125 mg

Canadian Trade Name(s)

• N/A

Canadian Availability

• N/A

UK Trade Name(s)

• N/A

UK Availability

• N/A

Australian Trade Name(s)

• N/A

Australian Availability

• N/A

[Outline]

Neurologic

Cholinergic Muscle Stimulants

Drug Name: Guanidine 125 MG Oral Tablet

Ingredient(s): Guanidine

Imprint: KEY;74

Color(s): White

Shape: Round

Size (mm): 10.00

Score: 1

Inactive Ingredient(s): colloidal silicon dioxide / magnesium stearate / mannitol / microcrystalline cellulose

Drug Label Author:
Key Pharmaceuticals, Inc.

DEA Schedule:
Non-Scheduled